US Approves Cannabis Research For Veterans With PTSD
After three years of negotiating with the FDA, MAPS gets cannabis study approved in the US
Psychedelic organization MAPS — responsible for negotiating clinical research for sacred medicine like psilocybin, LSD, MDMA and Cannabis — received $12.9 million dollars to run a study on the benefits of cannabis on veterans suffering with PTSD. The study was first proposed in 2021 when it was put on hold by the FDA. Recently, in the end of 2024, the FDA changed their minds after MAPS made a few changes in the study.
You can read the official statement made by MAPS about the subject in the following link:
Let’s go over the basic design of the study, why the FDA put the study on hold for three years, and why they changed their minds and approved the study.
The approval of this study is important because it paves the path to other researches that focus on the benefits of…
